| 產(chǎn)品描述： | LY 344864 is a selective, orally active 5-HT1F receptor agonist with a Ki of 6 nM. LY 344864 is a full agonist producing an effect similar in magnitude to serotonin itself. LY 344864 can cross the blood brain barrier to some extent |
| 靶點： |
human 5-HT1F Receptor：0.006 μM (Ki)；human 5-HT1A Receptor：0.530 μM (Ki)；human 5-HT1B Receptor：0.549 μM (Ki)；human 5-HT1D Receptor：0.575 μM (Ki)；human 5-HT1E Receptor：1.415 μM (Ki)；human 5-HT2B Receptor：1.695 μM (Ki)；Human 5-HT2A Receptor：3.499 μM (Ki)；Human 5-HT3A Receptor：3.935 mM (Ki)；Human 5-HT7 Receptor：4.851 μM (Ki)；rat α2-adrenergic receptor：3.69 μM (Ki)；rat α1-adrenergic receptor：5.06 μM (Ki) |
| 體內(nèi)研究： |
LY 344864 (0-10 ng/kg; p.o. or i.v.; once) inhibits neurogenic dural inflammation in rat migraine pain model. LY 344864 (1 mg/kg; i.v.; once) can cross the blood brain barrier to some extent in rats. LY 344864 (2 mg/kg; i.p.; daily for 14 days) attenuates dopaminergic neuron loss and improved behavioral endpoints in a Parkinson’s disease mouse model |
| 參考文獻(xiàn)： |
1. Phebus LA, Johnson KW, Zgombick JM, Characterization of LY344864 as a pharmacological tool to study 5-HT1F receptors: binding affinities, brainpenetration and activity in the neurogenic dural inflammation model of migraine. Life Sci. 1997;61(21):2117-26. 2. Scholpa NE, et al. 5-HT1F receptor-mediated mitochondrial biogenesis for the treatment of Parkinson's disease. Br J Pharmacol. 2018 Jan;175(2):348-358. |
| 溶解性： |
Soluble in DMSO |
| 保存條件： |
RT |
| 配置溶液濃度參考： |
|
1mg |
5mg |
10mg |
| 1 mM |
2.578 ml |
12.891 ml |
25.781 ml |
| 5 mM |
0.516 ml |
2.578 ml |
5.156 ml |
| 10 mM |
0.258 ml |
1.289 ml |
2.578 ml |
| 50 mM |
0.052 ml |
0.258 ml |
0.516 ml |
|
| 注意： |
部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶參考交流研究之用。 |
上海工商
危險品化學(xué)品經(jīng)營許可證（不帶存儲）
營業(yè)執(zhí)照(三證合一)
北京